Skip to main content
. 2009 May;16(3):50–54. doi: 10.3747/co.v16i3.444

TABLE I.

Anti-angiogenic agents

Target Agent Description
vegf ligand Bevacizumab (Avastina) Humanized anti-vegfa monoclonal antibody
Aflibercept (vegf Trapb) Fusion protein of vegfr-1, vegfr-2, and immunoglobulin G1 Fc fragment
vegf receptor
  Extracellular domain IMC-1121B Human anti–vegfr-2 monoclonal antibody
  Cytoplasmic domain AEE788 vegfr-2 and egfr inhibitor
Axitinib (AG-013736) vegfr-1,2 and pdgfr inhibitor
BMS-582664 vegfr-2 and fgfr inhibitor
Motesanib (AMG-706) vegfr-1,2,3; pdgfrb; and c-Kit inhibitor
OSI-930 vegfr-2 and c-Kit inhibitor
Pazopanib (GW-786034) vegfr-2 inhibitor
Tandutinib (MLN-518) Flt-3, pdgfr, c-Kit inhibitor
Vatalanib (PTK787) vegfr-1,2,3 and pdgfrb inhibitor
Sorafenib (BAY 43–9006) b-Raf; vegfr-2,3; pdgfrb; Flt-3; and c-Kit inhibitor
Sunitinib (SU11248) vegfr-1,2; pdgfra, pdgfrb; and c-Kit inhibitor
Cediranib (AZD2171) vegfr-1,2,3; pdgfrb; and c-Kit inhibitor
Vandetanib (ZD6474) vegfr-2,3 and egfr inhibitor
XL-184 vegfr-2, Met, c-Kit, Flt-3, and Tie2 inhibitor
XL-999 vegfr-1,2,3; fgfr; pdgfr; and Flt-3 inhibitor
Endogenous inhibitors Angiostatin Cleavage fragment of plasminogen
Endostatin Cleavage fragment of collagen xviii
Thrombospondin 1 Extracellular glycoprotein
Other EMD 121974 (Cilengitidec) αvβ3 Integrin receptor inhibitor
ATN-161 αvβ1 Integrin receptor inhibitor
Volociximab αvβ1 Integrin receptor inhibitor
Vitaxin Human monoclonal antibody to αvβ3 integrin receptor
AMG-386 Angiopoietin inhibitor
Thalidomide Immunomodulatory agent
AGN-745/SIRNA027 sirna inhibiting vegfr-1 mrna
a

Genentech, San Francisco, CA, U.S.A.

b

Regeneron, Tarrytown, NY, U.S.A.

c

Merck and Co., Whitehouse Station, NJ, U.S.A.

vegf = vascular endothelial growth factor; vegfr = vascular endothelial growth factor receptor; egfr = epidermal growth factor receptor; pdgfr[a,b] = platelet-derived growth factor receptor [α, β]; fgfr = fibroblast growth factor receptor.